Cruz et al. report that variants of TNF receptor 1 (TNFR1) found in patients with systemic juvenile idiopathic arthritis induce an inflammatory phenotype caused by cellular stress through dysfunction of multiple cellular trafficking pathways. The cover image shows super-resolution microscopy of an HT1080 cell harboring a variant of TNFR1, K203X (green), that preferentially sequesters intracellularly to the Golgi complex (red). The nucleus is stained with Hoechst 33342 (blue). Image credit: Davide Randazzo.
CD4⁺ T cells coordinate protective immunity against pathogens. However, how human CD4⁺ T cell memory is established and evolves following primary and repeated vaccinations remain incompletely understood. Using COVID-19 mRNA vaccination as a model, we tracked 50 distinct antigen-specific populations directly ex vivo with peptide–MHC class II tetramers in eight SARS-CoV-2–naïve individuals from pre-exposure baseline through memory time points after three mRNA doses. We showed that primary vaccination established the architecture of antigen-specific memory. Initial vaccination leveraged pre-existing memory while preferentially recruiting high-avidity T cells, establishing an immunodominance hierarchy dominated by a small subset of precursors. Booster vaccination refined both the magnitude and quality of T cell memory. It increased select populations and enhanced differentiation of subdominant CD4⁺ T cells. Populations that did not become more abundant after boosting retained their polyfunctional potential. Beyond establishing memory to the ancestral spike, vaccinations recruited cross-reactive T cells and increased the breadth of CD4+ T cell memory. Collectively, these findings reveal how human T cell memory evolves through sequential immunizations to generate a functionally diverse and broadly responsive memory repertoire against future viral challenges.
Yi-Hui Lai, Xi Su, Silina Awad, Asgar Ansari, Juneil Jang, Ali O. Saber, Huang-Wen Chen, Hannah Jung, Annesha Sarkar, Elizabeth M. Drapeau, Warren B. Bilker, Scott E. Hensley, Laura F. Su
Through a genome-wide forward CRISPR/Cas9 screen in interleukin-3 (IL3)-dependent Ba/F3 cells, we identified osteoclastogenesis-associated transmembrane protein 1 (OSTM1) as a previously unrecognized tumor suppressor. Analysis of patient datasets revealed that OSTM1 is frequently deleted or downregulated in human B-cell malignancies (BCM). In mice, Cd19-Cre-driven B cell–specific monoallelic or biallelic deletion of Ostm1 cooperated with Cdkn2a loss to drive lymphomagenesis with near-complete penetrance. Mechanistically, OSTM1 directly interacts with phosphodiesterase 3B (PDE3B) and promotes its proteasomal degradation. Because PDE3B hydrolyzes cyclic AMP (cAMP), loss of OSTM1 stabilizes PDE3B, leading to suppression of tumor-suppressive cAMP-dependent PKA/CREB signaling and promotion of oncogenic transformation. Consistent with this mechanism, PDE3B is frequently amplified or upregulated in BCM, and expression of CREB/CREBBP transcriptional targets correlates positively with OSTM1 expression but inversely with PDE3B across BCM cohorts. Importantly, silencing Pde3b reverses oncogenic transformation driven by Ostm1 loss. Together, these findings establish OSTM1 as a tumor suppressor and uncover an OSTM1/PDE3B/cAMP signaling axis that restrains B-cell lymphomagenesis and may represent a therapeutically actionable vulnerability.
Muhammad Usama Tariq, Namratha Sheshadri, Jianliang Shen, Jaeyong Jung, Rongrong Li, Hassan Sajjad, Mark C. Koch, Kevin Lu, Junrong Yan, Barbara Rosati, Giuseppe Caso, Brinda Vallat, Stephen K. Burley, Jun Wang, Christina Glytsou, Yi Sun, Tong Liu, Hong Li, Suzie Chen, Jiekun Yang, Zhiyuan Shen, Richard Z. Lin, Christian S. Hinrichs, Francesco Bertoni, Y. Lynn Wang, Jean Vacher, Ping Xie, Wei-Xing Zong
Dan Wang, Wenbin Ye, Jingjing Lyu, Xinzhi Hu, Weifan Yin, Dadmehr Yaghoubi, Chaorong Chen, Ran Jing, Ravi Dave, Qin Yang, Ya Cui, Tamer Sallam
Neurogenic inflammation is one component that sculpts the immune milieu of solid tumors. However, it remains unclear how the sensory-neuroimmune axis shapes the immune microenvironment in cold tumors to bolster treatment resistance. Using orthotopic head and neck squamous cell carcinoma (HNSCC) models, we demonstrate tumor growth-induced sensory hyperexcitability, and that surgical sensory signaling interruption reduced tumor growth. Genetic knockout of a key neuropeptide released by sensory neurons, calcitonin gene-related peptide (CGRP), encoded by Calca, produced eradication when paired with radioimmunotherapy. Such treatment reduced Treg infiltration and immunosuppressive function in Calca knockout mice. We also observed that high-dose psilocybin functions as a CGRP inhibitor and transiently reduces tumor growth by increasing antitumor immunity. Additionally, psilocybin increased circulating serotonin, which was partially reversed with platelet activation inhibitor, clopidogrel. We observed differential effects on CD8 and Treg functionality by psilocin in vitro. Correlational analyses in plasma from human subjects following a single-dose psilocybin corroborated these findings. Together, this work underscores the complex interaction of neurogenic inflammation and the tumor immune microenvironment, highlighting a potential therapeutic avenue for HNSCC and other solid tumors.
Shaquia L. Idlett-Ali, Alexander T.H. Nguyen, Khalid N.M. Abdelazeem, Diemmy Nguyen, Nicholas A. Olimpo, Michael Knitz, Jacob Gadwa, Tyler Weiskpof, Chloe Hodgson, Harshita Kumar, David Ceja Galindo, Teddi Gray, Sidharth V. Puram, Daniel L. Miller, Ginger E. Nicol, Anthony J. Saviola, Douglas G. Osborne, Sana D. Karam
Donor-specific transplantation tolerance promises to free recipients from complications associated with lifelong immunosuppression. Anergy, a CD4+ conventional T cell (Tconv)-intrinsic state of long-term hypofunction, is thought to arise when T cells encounter cognate antigen in the absence of costimulation. Anti-CD154 (αCD154), an antibody that blocks T cell costimulation and is currently in clinical trials, can induce donor-specific transplantation tolerance in mice in association with anergy of Tconvs recognizing persistently expressed alloantigens. Using murine models of fully mismatched cardiac allograft tolerance or repeated alloantigen exposure, we demonstrate that αCD154 is not sufficient and regulatory T cells (Tregs) are necessary to induce and sustain αCD154-mediated alloreactive Tconv anergy. Transient depletion of Tregs disrupted the induction of αCD154-mediated Tconv anergy, and in mice with established tolerance, Treg depletion transcriptionally and functionally reinvigorated previously anergic Tconvs. Mechanistically, Treg depletion increased IL-2 availability and IL-2R signaling in Tconvs, and exogenous IL-2 could bypass Treg-mediated control to partially restore Tconv function. Thus, the state of αCD154-mediated Tconv anergy is less cell-intrinsic than previously thought and requires Tregs to limit IL-2 availability for both its induction and its continuous enforcement. Selecting immunosuppressive drugs that preserve this Treg function may be critical for achieving stable clinical transplantation tolerance.
Alexandra Cassano, Domenic Abbondanza, Ying Wang, Shuang Wu, Christine M. McIntosh, Peter Wang, Jennifer B. Allocco, Montserrat Kwan, Ricardo Mora-Cartin, Ephraim Craddock, Michael S. Andrade, Anita S. Chong, Maria L. Alegre
Breast cancer is the most common cancer in women worldwide, with more than 2 million women diagnosed each year. This series of reviews, curated by Dr. Rinath Jeselsohn, highlights recent breakthroughs in therapeutic development that are changing the outlook for breast cancer patients, including improvements in immunotherapy, antibody-drug conjugates, endocrine therapies, and kinase inhibitors.
×
In this episode, Sai Prasad Pydi, Simran Singh, and Ashish Kumar describe how obesity-associated inflammation impairs pancreatic β cell function, yet the mechanisms by which immune cells acutely regulate insulin secretion remain poorly defined...